Skip to main content

Immunoglobulin Market to Exhibit CAGR of 7.0% and Hit USD 18,378.0 Million by 2025; Rising Awareness Regarding Immunoglobulins to Boost Market, states Fortune Business Insights™

Written by Customer Service on . Posted in Mergers And Acquisitions.

Pune, India, March 04, 2021 (GLOBE NEWSWIRE) — According to the report, Immunoglobulin market size is projected reach USD 18,378.0 Million by 2025. Global Immunoglobulin market was USD 10,750.0 million in 2018 and is anticipated to exhibit a CAGR of 7.0% during the forecast period set between 2019 to 2025. R The increasing diagnosis rates owing to escalating awareness regarding the treatment of immunoglobulins will have a tremendous effect on the market during the forecast period.The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic.
Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/immunoglobulins-market-100571
Introduction of Advanced Therapeutic to Augment GrowthThe launch of novel advanced drugs such as CUVITRU and BIVIGAM by Shire (Takeda Pharmaceutical Company Limited) and ADMA Biologics Inc., respectively will impel manufactures to innovative drugs and give competition to the rival companies, which, in turn, will spur opportunities for the market. The increasing adoption of immunoglobulin therapy as the first line of treatment for the primary immunodeficiency and other rare immunological and neurological diseases will be a critical factor in promoting the growth of the market.The growing focus on the diagnosis of immune disorders will foster the healthy growth of the market. The increasing prevalence of numerous viruses and diseases has led to pre-diagnosis, which, in turn, will augur well for the market. The growing efficiency of immunoglobulin as an effective treatment option for several diseases such as primary immunodeficiency and chronic inflammatory demyelinating polyneuropathy (CIDP) will positively enable speedy expansion of the market in the foreseeable future.
Click here to get the short-term and long-term impacts of COVID-19 on this Market:https://www.fortunebusinessinsights.com/industry-reports/immunoglobulins-market-100571
The market in North America generated a revenue of US$ 6,291.5 Mn in 2017 and is and is predicted to remain dominant during the forecast period. The growth in the region is attributed to the acceptance of immunoglobulin as a first line of treatment for many critical immune disorders.Rising Patient Population to Aid Expansion in North AmericaThe increasing number of patients and the growing demand for novel therapies will further aid the growth of the market in the region.  Asia Pacific is predicted to hold the largest share in the market owing to the demand for intravenous (IV) in the developing nations.The increasing healthcare expenditure and rising investment for advanced immunoglobulins will further enable growth in the region. The Middle and Africa is likely to expand in the forthcoming years owing to the developing healthcare infrastructure in the region.
Quick Buy –  Immunoglobulin Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/100571
Key Players:Shire (Takeda Pharmaceutical Company Limited)CSL BehringGrifols, S.A.Kedrion S.p.AOctapharmaBio Products Laboratory Ltd.Biotest AGChina Biologic Products Holdings, Inc.LFB SAShanghai RAAS Blood Products Co., Ltd.
Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/immunoglobulins-market-100571
Global Immunoglobulin Market Segmentations:By Route of AdministrationIntravenous (IV Subcutaneous (SC))By IndicationPrimary ImmunodeficiencyChronic Inflammatory Demyelinating Polyneuropathy (CIDP)Guillain-Barre Syndrome (GBS)Immune Thrombocytopenic Purpura (ITP)Multifocal Motor Neuropathy (MMN))By Form:LiquiLyophilizedBy End UserHospitalsClinicsHomecareBy GeographyNorth America (U.S. and Canada)Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)Latin America (Brazil, Mexico, and Rest of Latin America)Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)
Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/immunoglobulins-market-100571
Have a Look at Related Reports:Kidney Stone Management Market Size, Share & COVID-19 Impact Analysis, By Type (Lithotripsy, Ureteroscopy, and Percutaneous Nephrolithonomy (PCNL) By End User (Hospitals, Specialty Clinics, and Ambulatory Surgical Centers), and Regional Forecast, 2020-2027Dental Materials Market Size, Share & COVID-19 Impact Analysis, By Type (Metallic Biomaterials, Ceramic Biomaterials, Polymers, Natural Biomaterials, and Others), By Application (Implant, Prosthetics, and Orthodontics), By End User (Dental Product Manufacturers, Dental Laboratories, and Others), and Regional Forecast, 2020-2027Intensive Care Unit (ICU) Equipment Market Size, Share and Covid-19 Impact Analysis, By Product (Beds, Ventilators, Pulse Oximeters, Dialysis Equipment, and Others), By Patient (Adult and Pediatric), By Application (Neurology, Cardiology, Respiratory, Renal, Oncology, Trauma, and Others), By End-User (Hospitals, Specialty Clinics, and Others) and Regional Forecast, 2020-2027Bone Graft Substitutes Market Size, Share & COVID-19 Impact Analysis, By Type (Autograft, Allograft, Demineralized Bone Matrix (DBM), Synthetic, and Xenograft), By Application (Spinal Fusion, Joint Reconstruction, Foot & Ankle, and Others), By End User (Hospitals, and Specialty Clinics), and Regional Forecast, 2020-2027Cystic Fibrosis Market Size, Share & Covid-19 Impact Analysis, By Drug Class (Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), Bronchodilators, Mucolytic, Pancreatic Enzyme Supplement, and Others), By Route of Administration (Oral, and Parenteral), By Distribution Channel (Retail Pharmacies & Drug Stores, Online Pharmacies, and Hospital Pharmacies), and Regional Forecast, 2020-2027
About Us:Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Contact Us:Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune – 411045, Maharashtra, India.
Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Fortune Business Insights™
LinkedIn | Twitter | Blogs

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.